The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Differential induction of antibody-dependent cellular cytotoxicity (ADCC) against human EGFR-expressing NSCLC cell lines by necitumumab, cetuximab, and panitumumab.
D. Patel
No relevant relationships to disclose
B. Saxena
No relevant relationships to disclose
Q. Zhou
No relevant relationships to disclose
W. Walton
No relevant relationships to disclose
R. Srikakulum
No relevant relationships to disclose
R. Manteiga
No relevant relationships to disclose
J. Haurum
No relevant relationships to disclose
J. R. Tonra
No relevant relationships to disclose
X. Kang
No relevant relationships to disclose